Paola Neri

5.7k total citations · 2 hit papers
152 papers, 3.5k citations indexed

About

Paola Neri is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Paola Neri has authored 152 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Hematology, 89 papers in Molecular Biology and 65 papers in Oncology. Recurrent topics in Paola Neri's work include Multiple Myeloma Research and Treatments (113 papers), Protein Degradation and Inhibitors (41 papers) and Peptidase Inhibition and Analysis (27 papers). Paola Neri is often cited by papers focused on Multiple Myeloma Research and Treatments (113 papers), Protein Degradation and Inhibitors (41 papers) and Peptidase Inhibition and Analysis (27 papers). Paola Neri collaborates with scholars based in Canada, United States and Italy. Paola Neri's co-authors include Nizar J. Bahlis, Pierfrancesco Tassone, Nikhil C. Munshi, Kenneth C. Anderson, Dharminder Chauhan, Peter Duggan, Maria Leggio, Laura Mandolesi, Alessandro Di Graziano and Teru Hideshima and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Paola Neri

140 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response

2023 120 citations Sarthak Sinha, Paola Neri et al. profile →
Multiple myeloma

2024 72 citations Paola Neri, Nizar J. Bahlis et al. Nature Reviews Disease Primers profile →

Peers

Countries citing papers authored by Paola Neri

Since Specialization

Citations

This map shows the geographic impact of Paola Neri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paola Neri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paola Neri more than expected).

Fields of papers citing papers by Paola Neri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paola Neri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paola Neri. The network helps show where Paola Neri may publish in the future.

Co-authorship network of co-authors of Paola Neri

This figure shows the co-authorship network connecting the top 25 collaborators of Paola Neri. A scholar is included among the top collaborators of Paola Neri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paola Neri. Paola Neri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Doubling down on GPRC5D in multiple myeloma 2025 ·Blood ·Paola Neri	0
2	Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Melanie M. Frigault, Beatrix Stelte‐Ludwig, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Ranjan Maity, Nizar J. Bahlis, Paola Neri, Aru Narendran	1
3	Multiple myeloma breakdown → 2024 ·Nature Reviews Disease Primers ·(unknown), Paola Neri, Nizar J. Bahlis, Evangelos Terpos, Nour Moukalled, Vânia Hungria, Salomon Manier, Mohamad Mohty	72
4	Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma 2024 ·Blood ·Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Sungwoo Ahn, Mansour Poorebrahim, Elie Barakat, (unknown), Noémie Leblay, Bachisio Ziccheddu, Benjamin Diamond, (unknown), Adam D. Cohen, Ola Landgren, Paola Neri, Francesco Maura, Nizar J. Bahlis	16
5	Cereblon-Targeting Ligase Degraders in Myeloma 2024 ·Hematology/Oncology Clinics of North America ·Holly Lee, Paola Neri, Nizar J. Bahlis	2
6	Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC) 2023 ·Leukemia & lymphoma ·Daniel L. Levin, (unknown), (unknown), Holly Lee, Jason Tay, Peter Duggan, Paola Neri, Nizar J. Bahlis, Víctor H. Jiménez‐Zepeda	0
7	Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency 2023 ·Blood ·Noémie Leblay, Sungwoo Ahn, (unknown), Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence Boise, Nizar J. Bahlis, Paola Neri	14
8	Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells 2023 ·Blood ·Mansour Poorebrahim, Holly Lee, Sacha Benaoudia, Ranjan Maity, Sungwoo Ahn, Noémie Leblay, Elie Barakat, (unknown), Douglas J. Mahoney, Lawrence Boise, Paola Neri, Nizar J. Bahlis	2
9	Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma 2023 ·Critical Reviews in Oncology/Hematology ·Paola Neri, Inger S. Nijhof	2
10	N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution 2021 ·Annals of Hematology ·Víctor H. Jiménez‐Zepeda, Holly Lee, Jason Tay, Peter Duggan, (unknown), Paola Neri, Nizar J. Bahlis	3
11	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma 2020 ·Clinical Cancer Research ·William E. Pierceall, Michael Amatangelo, Nizar J. Bahlis, David S. Siegel, Adeeb Rahman, Oliver Van Oekelen, Paola Neri, Mary H. Young, (unknown), Natalya V. Serbina, Samir Parekh, Amit Agarwal, Anjan Thakurta	27
12	Bortezomib-Maintenance for Patients with AL Amyloidosis: A Single Center Experience 2017 ·Blood ·Víctor H. Jiménez‐Zepeda, Peter Duggan, Paola Neri, Jason Tay, Nizar J. Bahlis	2
13	Single Cell Resolution Profiling Defines the Innate and Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs Treatment in Multiple Myeloma (MM) 2017 ·Blood ·Paola Neri, Ranjan Maity, (unknown), Peter Duggan, (unknown), Víctor H. Jiménez‐Zepeda, Jason Tay, Lawrence Boise, Anjan Thakurta, Nizar J. Bahlis	15
14	The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort 2017 ·Blood ·(unknown), Víctor H. Jiménez‐Zepeda, Nizar J. Bahlis, Paola Neri, Irwindeep Sandhu, Michael P. Chu, Ismail Ismail, Jason Tay, Peter Duggan, Andrew Belch, (unknown), Linda M. Pilarski, (unknown), Christopher P. Venner	1
15	Minimal Residual Disease (MRD) Assessed By Flow Cytometry in Patients with AL Amyloidosis Treated with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 2017 ·Blood ·Víctor H. Jiménez‐Zepeda, Peter Duggan, Paola Neri, Jason Tay, Nizar J. Bahlis	4
16	14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors 2017 ·Leukemia ·Yong Gu, Ke Xu, (unknown), Mehmet Samur, Benjamin G. Barwick, Manali Rupji, Jyoti Arora, Paola Neri, Jonathan L. Kaufman, Ajay K. Nooka, Leon Bernal‐Mizrachi, Paula M. Vertino, (unknown), (unknown), Nikhil C. Munshi, Haian Fu, Jeanne Kowalski, Lawrence Boise, Sagar Lonial	14
17	Reovirus modulates autophagy during oncolysis of multiple myeloma 2013 ·Autophagy ·Chandini M. Thirukkumaran, Zhong Qiao Shi, Joanne Luider, Karen Kopciuk, He Gao, Nizar J. Bahlis, Paola Neri, Mark Pho, Doug Stewart, Adnan Mansoor, Don Morris	43
18	Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma 2012 ·Clinical Cancer Research ·Chandini M. Thirukkumaran, Zhong Qiao Shi, Joanne Luider, Karen Kopciuk, He Gao, Nizar J. Bahlis, Paola Neri, Mark Pho, Douglas A. Stewart, Adnan Mansoor, Don Morris	60
19	Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib 2008 ·Blood ·Addolorata Maria Luce Coluccia, Teresa Cirulli, Paola Neri, Domenica Mangieri, Maria Cristina Colanardi, Antonio Gnoni, Nicola Di Renzo, Franco Dammacco, Pierfrancesco Tassone, Doménico Ribatti, Carlo Gambacorti‐Passerini, Angelo Vacca	79
20	In vivo and in vitro cytotoxicity of R‐etodolac with dexamethasone in glucocorticoid‐resistant multiple myeloma cells 2006 ·British Journal of Haematology ·Paola Neri, Hiroshi Yasui, Teru Hideshima, Pierfrancesco Tassone, Noopur Raje, (unknown), Kenji Ishitsuka, Simona Blotta, Tanyel Kiziltepe, Enrique M. Ocio, Mariateresa Fulciniti, (unknown), Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact